Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics

被引:14
作者
Misri, Ripen [1 ]
Wong, Nelson K. Y. [1 ]
Shenoi, Rajesh A. [2 ,3 ]
Lum, Christine M. W. [1 ]
Chafeeva, Irina [2 ,3 ]
Toth, Karoly [4 ]
Rustum, Youcef [4 ]
Kizhakkedathu, Jayachandran N. [2 ,3 ,5 ]
Khan, Mohamed K. [1 ,6 ]
机构
[1] BC Canc Res Ctr, Dept Expt Therapeut, Vancouver, BC, Canada
[2] Univ British Columbia, Ctr Blood Res, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada
[4] Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA
[5] Univ British Columbia, Dept Chem, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Surg, Vancouver, BC V6T 1W5, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Hyperbranched polyglycerol; Nanoparticles; Biodistribution; Drug delivery; Docetaxel; BIOLOGICAL EVALUATION; IN-VITRO; NAB-PACLITAXEL; NANOPARTICLES; BIODISTRIBUTION; CANCER; THERAPY; CELLS; BIOCOMPATIBILITY; GEMCITABINE;
D O I
10.1016/j.nano.2015.04.016
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
We report the synthesis and characterization of a polymeric nanoparticle (NP) based on hyperbranched polyglycerol (HPG) containing a hydrophobic core and a hydrophilic shell, and assessed its suitability to be developed as a systemic anticancer drug carrier. HPG NP displayed low toxicity to primary cell cultures and were well-tolerated in mice after intravenous administration. When tested in mice tumor xenograft models, HPG NP accumulated significantly in the tumors with low accumulation in the liver and the spleen. In vitro studies demonstrated that HPG NP was capable of hydrophobically binding docetaxel and releasing it in a controlled manner. The HPG NP formulation of docetaxel conferred a preferential protective effect on primary non-cancerous cells while effectively killing cancer cells, indicating great potential for widening its therapeutic index. Taken together, these data indicate that HPG NP is a highly promising nanocarrier platform for systemic delivery of anticancer drugs. From the Clinical Editor: The use of polyethylene glycol on nano-carriers as "stealth" to deliver intravenous drugs is well known. Here, the authors developed polymeric nanoparticle (NP) with hyperbranched polyglycerol (HPG) and tested its efficacy in delivering docetaxel. The results showed that this formulation could preferentially killed cancer cells with a high therapeutic index. It seems that this platform could have a great potential in cancer therapy. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:1785 / 1795
页数:11
相关论文
共 40 条
[1]   Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[2]   Dendritic Polyglycerols for Biomedical Applications [J].
Calderon, Marcelo ;
Quadir, Mohiuddin Abdul ;
Sharma, Sunil Kumar ;
Haag, Rainer .
ADVANCED MATERIALS, 2010, 22 (02) :190-218
[3]   Biodistribution of sub-10 nm PEG-modified radioactive/upconversion nanoparticles [J].
Cao, Tianye ;
Yang, Yang ;
Sun, Yun ;
Wu, Yongquan ;
Gao, Yuan ;
Feng, Wei ;
Li, Fuyou .
BIOMATERIALS, 2013, 34 (29) :7127-7134
[4]   Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives [J].
Cheng, Yiyun ;
Zhao, Libo ;
Li, Yiwen ;
Xu, Tongwen .
CHEMICAL SOCIETY REVIEWS, 2011, 40 (05) :2673-2703
[5]   Dendrimer biocompatibility and toxicity [J].
Duncan, R ;
Izzo, L .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (15) :2215-2237
[6]   Docetaxel-Albumin Conjugates: Preparation, In Vitro Evaluation and Biodistribution Studies [J].
Esmaeili, Farnaz ;
Dinarvand, Rassoul ;
Ghahremani, Mohammad Hossein ;
Amini, Mohsen ;
Rouhani, Hasti ;
Sepehri, Nima ;
Ostad, Seyed Nasser ;
Atyabi, Fatemeh .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (08) :2718-2730
[7]   The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect [J].
Fang, Jun ;
Nakamura, Hideaki ;
Maeda, Hiroshi .
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (03) :136-151
[8]   Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer [J].
Gradishar, William J. ;
Krasnojon, Dimitry ;
Cheporov, Sergey ;
Makhson, Anatoly N. ;
Manikhas, Georgiy M. ;
Clawson, Alicia ;
Bhar, Paul .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) :3611-3619
[9]   Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile [J].
Hrkach, Jeffrey ;
Von Hoff, Daniel ;
Ali, Mir Mukkaram ;
Andrianova, Elizaveta ;
Auer, Jason ;
Campbell, Tarikh ;
De Witt, David ;
Figa, Michael ;
Figueiredo, Maria ;
Horhota, Allen ;
Low, Susan ;
McDonnell, Kevin ;
Peeke, Erick ;
Retnarajan, Beadle ;
Sabnis, Abhimanyu ;
Schnipper, Edward ;
Song, Jeffrey J. ;
Song, Young Ho ;
Summa, Jason ;
Tompsett, Douglas ;
Troiano, Greg ;
Hoven, Tina Van Geen ;
Wright, Jim ;
LoRusso, Patricia ;
Kantoff, Philip W. ;
Bander, Neil H. ;
Sweeney, Christopher ;
Farokhzad, Omid C. ;
Langer, Robert ;
Zale, Stephen .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (128)
[10]  
Jokerst JV, 2011, NANOMEDICINE-UK, V6, P715, DOI [10.2217/nnm.11.19, 10.2217/NNM.11.19]